Compare QD & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QD | EMBC |
|---|---|---|
| Founded | 2014 | 1924 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.5M | 719.7M |
| IPO Year | 2017 | N/A |
| Metric | QD | EMBC |
|---|---|---|
| Price | $3.84 | $11.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 310.9K | ★ 781.4K |
| Earning Date | 11-24-2025 | 11-25-2025 |
| Dividend Yield | N/A | ★ 5.08% |
| EPS Growth | ★ 2364.38 | 20.90 |
| EPS | 0.67 | ★ 1.62 |
| Revenue | $12,647,260.00 | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.18 |
| Revenue Next Year | N/A | $0.09 |
| P/E Ratio | ★ $6.13 | $7.28 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.04 | $9.20 |
| 52 Week High | $5.08 | $21.23 |
| Indicator | QD | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 31.11 | 41.41 |
| Support Level | $3.89 | $11.46 |
| Resistance Level | $4.91 | $12.11 |
| Average True Range (ATR) | 0.18 | 0.67 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 1.83 | 25.50 |
Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.